New Score Predicts Risk for VTE in Those With Multiple Myeloma

WEDNESDAY, Aug. 7, 2019 -- A new risk prediction score outperforms current guidelines for predicting venous thromboembolism (VTE) in multiple myeloma (MM), according to a study published online Aug. 4 in the American Journal of Hematology. Kristen...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news

Related Links:

Both multiple myeloma and monoclonal gammopathy of undetermined significance (MGUS) are associated with increased venous thromboembolism (VTE) and arterial thrombosis [1]. The thrombogenicity of myeloma is multi-fold with current VTE risk stratification focusing predominantly on clinical factors. Key to augmenting our clinical risk assessment model to identify patients who may benefit from thromboprophylaxis is a predictive biomarker. Current coagulation testing are inadequate as they measure only the time to clot formation, making them poor indicators of a hypercoagulable state.
Source: Thrombosis Research - Category: Hematology Authors: Tags: Letter to the Editors-in-Chief Source Type: research
ConclusionThe results of this analysis emphasize the need for active management of patients with PV with appropriate HU dose titration to maintain blood count control while monitoring for signs and symptoms of HU intolerance.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Risk of developing Venous Thromboembolism in Multiple Myeloma; Based on current VTE risk assessment models : Impede VTE Score&IMWG guidelines Introduction.Venous thromboembolic events (VTE) are a common cause of morbid-mortality in patients with multiple myeloma(MM),occurring in about 10% of patients.The pathogenesis of thrombosis in the MM is multifactorial and includes patient, treatment and disease-related factors.It is demonstrated that the risk of VTE increases during the active phase and the risk is higher with the use of certain agents such as immunomodulators (IMIDs),especially in combination with high-dose of ...
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Treatment of Newly Diagnosed Myeloma Transplant Eligible Source Type: research
Condition:   Venous Thromboembolism Intervention:   Drug: Apixaban 2.5 MG Sponsors:   Instituto de Investigacion Sanitaria La Fe;   Bristol-Myers Squibb Active, not recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
In this study, we used large-scale electronic health records data from multiple linked UK databases to address these evidence gaps.MethodsFor this population-based cohort study, we used linked primary care, hospital, and cancer registry data from the UK Clinical Practice Research Datalink to identify cohorts of survivors of the 20 most common cancers who were 18 years or older and alive 12 months after diagnosis and controls without history of cancer, matched for age, sex, and general practice. We compared risks for a range of cardiovascular disease outcomes using crude and adjusted Cox models. We fitted interactions to in...
Source: The Lancet - Category: General Medicine Source Type: research
CONCLUSION: Thrombin generation appears to be higher in patients with myeloma compared with controls, especially in high-risk patients, and does not change significantly after treatment completion. PMID: 31421013 [PubMed - as supplied by publisher]
Source: International Journal of Laboratory Hematology - Category: Hematology Authors: Tags: Int J Lab Hematol Source Type: research
FRIDAY, Aug. 16, 2019 -- For patients with multiple myeloma (MM) receiving immunomodulatory drugs (IMiDs), a risk assessment model, SAVED, can predict the risk for venous thromboembolism (VTE), according to a study published in the July issue of the...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news
PNH and MPN are diseases associated with increased thrombosis. PNH clones are commonly found in other haematological diseases i.e. MDS and aplastic anemia. The presence of PNH clones was studied in consecutive MPN patients. A prevalence of 2% and an association with the JAK2 mutation was found. Presence of a PNH clone could potentially influence the clinical course of MPN.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Original Study Source Type: research
Paroxysmal nocturnal hemoglobinuria (PNH) and myeloproliferative neoplasm (MPN) are diseases associated with increased thrombosis. PNH clones are commonly found in other hematologic diseases, such as myelodysplastic syndromes and aplastic anemia. The presence of PNH clones was studied in consecutive MPN patients. A prevalence of 2% and an association with the JAK2 mutation was found. Presence of a PNH clone could potentially influence the clinical course of MPN.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Original Study Source Type: research
More News: Hematology | Myeloma | Pharmaceuticals | Study | Thrombosis